April 26, 2017 News by Joana Fernandes, PhD Sanofi Genzyme to Present New Data on MS Treatments Lemtrada and Aubagio Sanofi Genzyme will present new results on follow-up studies of its products Lemtrada (alemtuzumab) and Aubagio (teriflunomide), both of which have been approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The new data will be presented at the American Academy of Neurology (AAN) Annual MeetingĀ taking…
April 19, 2017 News by Patricia Inacio, PhD Sanofi Genzyme to Discuss Three Multiple Sclerosis Therapies at Boston Event Sanofi GenzymeĀ will discuss three of its multiple sclerosis therapies at theĀ American Academy of Neurology annual meetingĀ in Boston, April 22-28. The presentations will cover two approved treatments for relapsing MS ā LemtradaĀ (alemtuzumab) and AubagioĀ (teriflunomide) ā and one that has been in a Phase 1 clinical…
April 17, 2017 News by Joana Fernandes, PhD Genentech, Novartis, Sanofi Genzyme Support Nationwide 2017 ‘Walk MS’ Events Genentech, NovartisĀ and Sanofi Genzyme are sponsoring this yearās Walk MS, an annualĀ event to raise funds for multiple sclerosis (MS) and the National Multiple Sclerosis Society (NMSS). Genentech, a division of Roche, returns as an MS Walk sponsor for the second year and will promote the āMS Voiceā…
September 20, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Sanofi Releases Patients’ Views of Aubagio as Effective Treatment for Relapsing MS Sanofi GenzymeĀ presented positive results from itsĀ Phase 4 study into patient-reported assessments ofĀ Aubagio (teriflunomide), an approved oral treatmentĀ for relapsing forms of multiple sclerosis (RMS). Real-world patient responses were reported at the 32ndĀ Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recentlyĀ held in London. The clinical…
August 29, 2016 News by Patricia Silva, PhD Lemtrada to Treat Relapsing MS Now Part of New Brunswick, Canada, Drug Program The Government ofĀ New Brunswick added Ā Lemtrada (alemtuzumab), byĀ Sanofi Genzyme,Ā to the New Brunswick Prescription Drug Program (NBPDP) through special authorization for eligibleĀ patients with relapsing-remitting multiple sclerosis (RRMS). New BrunswickĀ joins other Canadian provinces, includingĀ Ontario, Saskatchewan,Ā Quebec, and Manitoba, in making this treatment available to RRMS patients, ages 18 andĀ older,Ā who have had…
July 25, 2016 News by Patricia Silva, PhD Ontario Adds Lemtrada, a Relapsing MS Therapy, to Its Drug Coverage Program Sanofi GenzymeĀ announced that the Government ofĀ Ontario has added Lemtrada (alemtuzumab) to the province’s Exceptional Access Program (EAP), opening coverage to the treatment for eligible patients with relapsing-remitting multiple sclerosis (RRMS). The programĀ facilitates patient access to drugs not funded on the Ontario Drug Benefit (ODB) Formulary, or those…
May 26, 2016 News by Patricia Silva, PhD Sanofi Genzyme Launches vs.MS Global Campaign to Raise Awareness on MS’ Physical and Emotional Burden Sanofi GenzymeĀ recently launched vs.MS, a global initiative to raise awareness of the often unspoken physical and emotional burden of relapsing multiple sclerosis (RMS) on people living with the disease and their care partners. OnĀ World MS DayĀ yesterday, the company called onĀ the MS community to learn more about the…
May 18, 2016 News by Patricia Silva, PhD Sanofi Genzyme and Johns Hopkins Partner on MS Research Projects into Disease Progression Sanofi GenzymeĀ announced that it entered into a research collaborationĀ withĀ the Johns Hopkins School of Medicine to betterĀ understand the underlying causes of disease progression in multiple sclerosis (MS). Sanofi GenzymeĀ has a number of research partnerships withĀ MS academic medical centers, focused on exploring the pathogenesis of MS and potential new…
April 20, 2016 News by Margarida Azevedo, MSc Sanofi Genzyme Presenting New Data on Lemtrada’s Beneficial Effects, Drawn from RRMS Extension Study, at AAN 2016 Sanofi GenzymeĀ is presenting promising data regarding brain volume and retinal nerve fibers in multiple sclerosis (MS) patients ā drawn from an ongoing extension study intoĀ the disease-modifying drugĀ alemtuzumab (Lemtrada) ā at the 2016 American Academy of Neurology (AAN) Annual Meeting Ā taking place in Vancouver, Canada, through April…
April 18, 2016 News by Patricia Silva, PhD Sanofi Genzyme Presenting New Data on Its Approved and Investigational Multiple Sclerosis Treatments at AAN Sanofi GenzymeĀ will present new data onĀ itsĀ approved multiple sclerosis (MS) treatments āĀ LemtradaĀ (alemtuzumab) and AubagioĀ (teriflunomide) ā at the 68thĀ annual meeting of the American Academy of Neurology (AAN), taking place in Vancouver, Canada, through April 21, as well asĀ data on investigational therapies in its pipeline. In total, the meeting…
March 21, 2016 News by Patricia Silva, PhD CONy16: Sanofi Genzyme Symposium on MS Therapies Targeting T and B Cells; Exclusive Interview with Lead Researcher Sanofi Genzyme,Ā one of the companies participatingĀ in the four-dayĀ 10th World Congress on Controversies in Neurology (CONy) in Lisbon, Portugal, that concludedĀ on March 20, 2016, supported several symposiums focused on multiple sclerosis (MS) ā including one on B-cell and T-cell therapies. For over a decade, Sanofi Genzyme has workedĀ to developĀ effective therapies…